Want to join the conversation?
$JNJ's focused execution has delivered 11 billion-dollar-plus brands. 10 of these brands are growing and 6 of them are growing double digits. Cumulatively, sales from the medicines launched since 2011 are the second highest of any pharmaceutical company. The company's R&D and commercial capabilities are a proven strong foundation for future growth.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.